Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody

Fuliang Chu, PhD, Jason R. Westin, MD, Min Zhang, Ph.D., Lei Feng, Veerabhadran Baladandayuthapani, PhD, Zhiqiang Wang, Rochelle Allen, RN, Michael Wallace, MD, Luis Vence, Laszlo Radvanyi, Larry W. Kwak, MD, PhD, Rinat Rotem-Yehudar, PhD, R Eric Davis, Sattva S. Neelapu, MD

Blood (2012) 120 (21): 162.

https://doi.org/10.1182/blood.V120.21.162.162

Published: 2012

Journal Articles

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Jason R. Westin, MD, Fuliang Chu, PhD, Luis E Fayad, MD, Larry W Kwak, MD, PhD, Nathan H Fowler, MD, Jorge E Romaguera, MD, F.B. Hagemeister, MD, Michelle Fanale, MD, Felipe Samaniego, M.D., Rochelle Allen, RN, Lei Feng, Ph.D, Veerabhadran Baladandayuthapani, PhD, Rinat Rotem-Yehudar, PhD, Sattva Neelapu, MD

Blood (2012) 120 (21): 793.

https://doi.org/10.1182/blood.V120.21.793.793

Published: 2012

Journal Articles

Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation

Blood (2012) 120 (21): 578.

https://doi.org/10.1182/blood.V120.21.578.578

Published: 2012

Journal Articles

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

Don M. Benson, Jr, Courtney E. Bakan, Anjali Mishra, Craig C. Hofmeister, Yvonne Efebera, Brian Becknell, Robert A. Baiocchi, Jianying Zhang, Jianhua Yu, Megan K. Smith, Carli N. Greenfield, Pierluigi Porcu, Steven M. Devine, Rinat Rotem-Yehudar, Gerard Lozanski, John C. Byrd, Michael A. Caligiuri

Blood (2010) 116 (13): 2286–2294.

https://doi.org/10.1182/blood-2010-02-271874

Published: 2010

Includes: Supplemental data

Journal Articles

CT-011, Anti-PD-1 Antibody, Enhances Ex-Vivo T Cell Responses to Autologous Dendritic/Myeloma Fusion Vaccine Developed for the Treatment of Multiple Myeloma.

Jacalyn Rosenblatt, M.D., Brett Glotzbecker, MD, Heidi Mills, Whitney Keefe, Kerry Wellenstein, Baldev Vasir, PhD, Zekui Wu, MD, Corrine Zarwan, MD, Michael Schickler, PhD, Rinat Rotem-Yehudar, PhD, Donald Kufe, MD, David Avigan, MD

Blood (2009) 114 (22): 781.

https://doi.org/10.1182/blood.V114.22.781.781

Published: 2009

Journal Articles

The Humanized Anti PD-1 Antibody, CT-011, Increases Specific CD4+ Effector/Memory and Memory T Lymphocytes in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Following Autologous Stem Cell Transplantation (AuSCT).

Rinat Rotem-Yehudar, PhD, Philippe Armand, MD, PhD, Steve Devine, MD, Joseph W. Fay, MD, Chitra Hosing, MD, Markus Y Mapara, Erica Campagnero, MD, Joseph P. Uberti, MD, PhD, David Avigan, MD, Karen K Ballen, MD, Jane N. Winter, MD, Arnon Nagler, MD, Leo I. Gordon, MD

Blood (2009) 114 (22): 1216.

https://doi.org/10.1182/blood.V114.22.1216.1216

Published: 2009

Journal Articles

In Vitro and In Vivo Effects of CT-011, a Humanized Anti–PD-1 Monoclonal Antibody, in Combination with Rituximab against Human B-Cell Lymphomas.

Fuliang Chu, PhD, Myriam Foglietta, MD, Hong Qin, MD, PhD, Rakesh Sharma, Ph.D., Qing Yi, MD, PhD, Galina Rodionov, Rinat Rotem-Yehudar, PhD, Sattva Neelapu, M.D.

Blood (2009) 114 (22): 724.

https://doi.org/10.1182/blood.V114.22.724.724

Published: 2009

NARROW

Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

CT-011, Anti-PD-1 Antibody, Enhances Ex-Vivo T Cell Responses to Autologous Dendritic/Myeloma Fusion Vaccine Developed for the Treatment of Multiple Myeloma.

The Humanized Anti PD-1 Antibody, CT-011, Increases Specific CD4+ Effector/Memory and Memory T Lymphocytes in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Following Autologous Stem Cell Transplantation (AuSCT).

In Vitro and In Vivo Effects of CT-011, a Humanized Anti–PD-1 Monoclonal Antibody, in Combination with Rituximab against Human B-Cell Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

CT-011, Anti-PD-1 Antibody, Enhances Ex-Vivo T Cell Responses to Autologous Dendritic/Myeloma Fusion Vaccine Developed for the Treatment of Multiple Myeloma.

The Humanized Anti PD-1 Antibody, CT-011, Increases Specific CD4+ Effector/Memory and Memory T Lymphocytes in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Following Autologous Stem Cell Transplantation (AuSCT).

In Vitro and In Vivo Effects of CT-011, a Humanized Anti–PD-1 Monoclonal Antibody, in Combination with Rituximab against Human B-Cell Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only